Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTAIQSN)

• DTT Name: Receptor-interacting protein 1 (RIPK1) DTT Info
• Gene Name: RIPK1

Molecule-Related Drug & Molecule List

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DNL758	DM89D6C	Cutaneous lupus erythematosus	EB5Z	Phase 2	[1]
Eclitasertib	DM2O8VW	Ulcerative colitis	DD71	Phase 2	[2]
GSK2982772	DM7HNFV	Plaque psoriasis	EA90.0	Phase 2	[3]
SAR443820	DMNCP7B	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[4]
GSK3145095	DM059OH	Pancreatic cancer	2C10	Phase 1/2	[5]
DNL104	DMOSCQ9	Alzheimer disease	8A20	Phase 1	[6]
DNL747	DMNSC0O	Alzheimer disease	8A20	Phase 1	[1]
R552	DM5XCRQ	Nervous system paraneoplastic or autoimmune disorders	8E4A.1	Phase 1	[1]

3 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tricyclic compound 10	DMV1RQX	N. A.	N. A.	Patented	[7]
Tricyclic compound 8	DMZI8GK	N. A.	N. A.	Patented	[7]
Tricyclic compound 9	DMF5E6U	N. A.	N. A.	Patented	[7]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GNE684	DMXVHOQ	Inflammation	1A00-CA43.1	Preclinical	[8]

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK'963	DMNOU59	Myeloid leukaemia	2B33.1	Investigative	[9]
PK68	DMIUZGY	Inflammation	1A00-CA43.1	Investigative	[10]
PMID24900635C21	DM1QDG0	Discovery agent	N.A.	Investigative	[11]
RIPA-56	DMYIQRK	Non-alcoholic fatty liver disease	DB92	Investigative	[12]

References

• [1] Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT05237284) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension. U.S.National Institutes of Health.
• [5] Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
• [6] DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.
• [7] Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.
• [8] Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. Cell Death Differ. 2021 Mar;28(3):985-1000.
• [9] Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009.
• [10] Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019 Jun 24;10(7):493.
• [11] Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med Chem Lett. 2013 Nov 4;4(12):1238-43.
• [12] Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635.